Three-Year Outcomes of Left Atrial Appendage Closure vs. Oral Anticoagulation in Atrial Fibrillation
The PRAGUE-17 study compares the three-year outcomes of left atrial appendage closure (LAAC) versus direct oral anticoagulation in patients with atrial fibrillation. LAAC was found to be non-inferior to NOACs for the primary composite endpoint, with similar incidence rates for secondary endpoints. T
0 views • 21 slides
Understanding Anticoagulants and Their Indications
Explore the world of anticoagulants through images, covering different types like warfarin and NOACs, their indications such as AF, DVT, and PE, monitoring in clinics, and specific drug details like apixaban, rivaroxaban, dabigatran, and edoxaban. Get insights into dosages, administration, and drug
0 views • 27 slides
Understanding Cardiac Utilization of Novel Oral Anticoagulants
Dive into the realm of cardiac anticoagulation, exploring the evolution from traditional methods like Warfarin to the modern use of Novel Oral Anticoagulants (NOACs). Discover the indications for long-term anticoagulation in conditions like atrial fibrillation and mechanical heart valves. Delve into
0 views • 46 slides
Plasma Levels of NOACs in Patients with NVAF: Single Centre Study
This study aims to characterize the plasma levels of Dabigatran, Rivaroxaban, and Apixaban in patients with non-valvular atrial fibrillation (NVAF) who have been taking these drugs for more than 4 days. The research also assesses median trough plasma levels of these anticoagulants, as well as their
0 views • 18 slides